Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. is a U.S.-based biomedical innovation company focused on developing therapeutic medical device technologies through partnerships with larger medical device companies. Its portfolio includes late-stage product candidates and strategic holdings centered on cardiovascular and surgical applications, with commercialization intended to be advanced through collaborators rather than a fully standalone sales model.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCardiovascular therapy platform developed for pacemaker-indicated hypertension patients.
Sirolimus-based balloon therapy product candidate for vascular intervention.
Intracorporeal organ retractors used in surgical procedures and sold in the U.S.
Collaborative development and commercialization arrangements with strategic partners.
Minority equity, royalty-stream and convertible interests in related device assets.
Products
Reported · share of revenue- Partnership Revenue98.2 %
- Products1.8 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
The company sells primarily to healthcare providers and medical device partners rather than to consumers. FreeHold products are sold to U.S. surgical customers, while AVIM Therapy and Virtue SAB are developed for commercialization through multinational device partners such as Medtronic and Terumo. Its customer base therefore includes hospitals, surgeons, electrophysiology/cardiology users, and strategic collaboration partners that fund or commercialize the technologies.
Buy FreeHold intracorporeal organ retractors for use in surgical procedures.
Collaborate on development, regulatory work and commercialization of AVIM Therapy and related assets.
Potential end users for AVIM Therapy in pacemaker-indicated hypertension patients.
Potential users of Virtue SAB in interventional cardiovascular procedures.
Strategy
The company’s strategy is to advance late-stage therapeutic device candidates through pivotal clinical development while sharing risk and commercialization burden with established device companies. It also seeks value creation through strategic holdings in adjacent assets and through selective product revenue from FreeHold. This model is designed to preserve focus on innovation while leveraging partner infrastructure for regulatory and market access.
Partnered development can accelerate regulatory and commercial pathways while limiting standalone build-out needs.
Late-stage assets can create value inflection points if clinical and regulatory milestones are achieved.
The existing product line provides direct product revenue and operating experience.
Geography
Orchestra BioMed is headquartered in the United States and its commercial product sales are currently limited to the U.S. FreeHold products are sold only in the United States, while its development partnerships are designed to support global commercialization if products are approved. The company’s exposure is therefore concentrated in U.S. healthcare demand today, with future international reach dependent on partner execution and regulatory approvals.
Risks
The business depends on successful clinical development, regulatory approvals and partner execution, so setbacks in any of those areas can delay or prevent commercialization. It also faces supply-chain concentration, competition from larger device companies, and the risk that product liability or safety issues could limit adoption or trigger regulatory action. Because much of the pipeline is still pre-commercial, the company remains exposed to execution risk and to the uncertainty of converting collaborations into durable revenue.
- Partner dependenceImpact: HighLikelihood: High
The business model relies on established device companies for development and commercialization support.
Exposure - Clinical and regulatory failureImpact: HighLikelihood: Medium
AVIM Therapy and Virtue SAB require successful trials and approvals before broad commercialization.
Exposure: Pipeline products
- Supply-chain concentrationImpact: HighLikelihood: Medium
Key components for Virtue SAB are sourced from single manufacturers in China and Singapore.
Exposure: Sirolimus and angioplasty balloons
- Product liability and safety riskImpact: MediumLikelihood: Medium
Adverse events or labeling changes can reduce market acceptance and trigger legal or regulatory actions.
Exposure: Approved or future therapeutic devices
- Competitive pressureImpact: MediumLikelihood: Medium
Larger device companies may have broader product lines, stronger distribution and more resources.
Exposure: Cardiovascular and surgical device markets
Accounting
Judgemental itemsMedtronic and Terumo arrangements may include distinct performance obligations and timing judgments.
Impact: Can shift revenue between periods and affect comparability
FreeHold sales are recognized on shipment, so order timing and inventory movements matter.
Impact: Quarterly revenue can be affected by shipment timing
Clinical trial and vendor obligations require management estimates of incurred but unpaid costs.
Impact: Can materially affect operating expenses and liabilities
Minority interests, royalty streams and convertible positions may need periodic valuation review.
Impact: Can create non-cash gains, losses or impairment charges
Similar listed companies
Publicly listed companies with a comparable business focus.
Oramed Pharmaceuticals Inc
ORMP · Pharmaceutical Preparations
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
Family Office Of America, Inc.
FOFA · Surgical & Medical Instruments & Apparatus
Odyssey Health, Inc.
ODYY · Surgical & Medical Instruments & Apparatus
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
Last updated: 24/09/2026